* Avidity Biosciences Inc reported a quarterly adjusted loss of 65 cents​​ per share for the quarter , higher than the same quarter last year, when the company reported EPS of -71 cents. The mean expectation of ten analysts for the quarter was for a loss of 71 cents per share. Wall Street expected results to range from -94 cents to -46 cents per share.

* Revenue fell 17.1% to $2.34 million from a year ago; analysts expected $4.27 million.

* Avidity Biosciences Inc's reported EPS for the quarter was a loss of 65 cents​.

* The company reported a quarterly loss of $80.4 million.

* Avidity Biosciences Inc shares had risen by 3.4% this quarter and gained 425.0% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 11.1% in the last three months.​

* In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Avidity Biosciences Inc is $64.00 This summary was machine generated from LSEG data November 8 at 09:03 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.71 -0.65 Beat

Jun. 30 2024 -0.79 -0.65 Beat

Mar. 31 2024 -0.78 -0.79 Missed

Dec. 31 2023 -0.66 -0.79 Missed